Lexaria Bioscience (LEXX) Amortizatization of Intangibles (2015 - 2026)
Lexaria Bioscience (LEXX) posted Amortizatization of Intangibles of $1664.0 for Q2 2026, down 7.66% sequentially from $1802.0 in Q1 2026, and down 24.33% YoY from $2199.0 in Q2 2025.
Lexaria Bioscience (LEXX) Amortizatization of Intangibles (2015 - 2026) Analysis & Trends
Lexaria Bioscience has reported Amortizatization of Intangibles for 5 years, with the latest figure at $1664.0 in Q2 2026.
- Quarterly Amortizatization of Intangibles fell 24.33% year-over-year to $1664.0 in Q2 2026, while the trailing twelve-month figure through May 2026 was $7473.0 (down 8.28% YoY) and the FY2025 annual result came in at $9047.0, up 35.6% from the prior year.
- Amortizatization of Intangibles retreated to $1664.0 in Q2 2026 per LEXX's latest filing, from $1802.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $2773.0 in Q1 2024 and troughed at $67.0 in Q4 2023.
- A 4-year average of $1920.2 and a median of $2070.0 in 2025 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2024 and 2026: Amortizatization of Intangibles jumped 3558.21% in 2024, then dropped 24.33% in 2026.
- Over 4 years, Amortizatization of Intangibles stood at $67.0 in 2023, then surged by 3558.21% to $2451.0 in 2024, then slipped by 20.97% to $1937.0 in 2025, then declined by 14.09% to $1664.0 in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $1664.0, $1802.0, and $1937.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | 1,664.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 1,664.00 |
| May 31, 2026 | 1,664.00 |
| Feb 28, 2026 | 1,802.00 |
| Feb 28, 2026 | 1,802.00 |
| Nov 30, 2025 | 1,937.00 |
| Nov 30, 2025 | 1,937.00 |
| Aug 31, 2025 | 2,070.00 |
| Aug 31, 2025 | 2,070.00 |
| May 31, 2025 | 2,199.00 |
| May 31, 2025 | 2,199.00 |
| Feb 28, 2025 | 2,327.00 |
| Feb 28, 2025 | 2,327.00 |
| Nov 30, 2024 | 2,451.00 |
| Nov 30, 2024 | 2,451.00 |
| Aug 31, 2024 | 1,171.00 |
| Aug 31, 2024 | 1,171.00 |
| May 31, 2024 | 2,661.00 |
| May 31, 2024 | 2,661.00 |
| Feb 29, 2024 | 2,773.00 |
| Feb 29, 2024 | 2,773.00 |